Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Advanced Pancreatic Cancer pipeline constitutes key companies continuously working towards developing Advanced Pancreatic Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Advanced Pancreatic Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/advanced-pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Pancreatic Cancer Market.

The Advanced Pancreatic Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Advanced Pancreatic Cancer Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Advanced Pancreatic Cancer treatment therapies with a considerable amount of success over the years.

*
Advanced Pancreatic Cancer companies working in the treatment market are Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others, are developing therapies for the Advanced Pancreatic Cancer treatment

*
Emerging Advanced Pancreatic Cancer therapies in the different phases of clinical trials are- IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others are expected to have a significant impact on the Advanced Pancreatic Cancer market in the coming years.

*
In March 2025, Swedish immunotherapy firm Anocca received regulatory approval in four European countries to conduct its Phase I/II VIDAR-1 clinical trial. This study will target patients with KRAS-positive advanced pancreatic cancer and will start by testing ANOC-001, Anocca's main product designed to target the KRAS G12V mutation.

*
In March 2025, Anocca AB, a prominent T-cell immunotherapy firm, received approval for its Clinical Trial Application (CTA) from regulatory bodies in four European countries under the EU's unified framework, with Germany serving as the reference country. The trial, VIDAR-1, is a Phase I/II multi-product umbrella study focused on patients with mutated KRAS-positive advanced pancreatic cancer. VIDAR-1 will evaluate several products, beginning with Anocca's lead candidate ANOC-001, which targets the mutant KRAS G12V. ANOC-001 is a novel innovation developed through Anocca's platform and will be produced at the company's in-house cGMP facility.

*
In December 2024, Novocure (NASDAQ: NVCR) announced that the pivotal Phase 3 PANOVA-3 trial achieved its primary goal, showing a statistically significant increase in median overall survival (mOS) compared to the control group. The PANOVA-3 study assessed Tumor Treating Fields (TTFields) therapy used alongside gemcitabine and nab-paclitaxel as a first-line treatment for patients with unresectable, locally advanced pancreatic adenocarcinoma.

*
In November 2024, Anocca AB, a prominent company specializing in T-cell receptor-engineered T-cell (TCR-T) therapies, has submitted its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for VIDAR-1, a Phase I/II multi-asset umbrella trial. The VIDAR-1 program will commence with ANOC-001, a therapy targeting mutant KRAS G12V in patients with advanced Advanced Pancreatic Cancer. Pending CTA approval, Anocca plans to launch the trial in the second quarter of 2025. ANOC-001 is the flagship product from Anocca's extensive preclinical pipeline of TCR-T cell therapies.

Advanced Pancreatic Cancer Overview

Advanced Pancreatic Cancer is a condition where malignant cells develop in the pancreatic tissues. This type of cancer originates within the pancreas, an abdominal organ positioned behind the lower portion of the stomach. The pancreas, resembling a slender pear lying horizontally, measures approximately 6 inches in length and serves as a gland in the body.

Get a Free Sample PDF Report to know more about Advanced Pancreatic Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/advanced-pancreatic-cancer-pipeline-insight [https://www.delveinsight.com/report-store/advanced-pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Advanced Pancreatic Cancer Drugs Under Different Phases of Clinical Development Include:

*
IMC-R117C: Immunocore

*
CT7001: Carrick Therapeutics

*
DK210: DEKA Biosciences

*
CMG901: Keymed Biosciences

*
AB011: CARsgen Therapeutics

*
Rintatolimod: AIM ImmunoTech Inc.

*
RXC004: Redx Pharma Plc

*
RAIN-32: Rain Oncology

*
Pamrevlumab: FibroGen

*
NIS793: Novartis AG

*
Pembrolizumab: Merck & Co

*
Lynparza: AstraZeneca

Advanced Pancreatic Cancer Route of Administration

Advanced Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Intravenous

*
Subcutaneous

*
Parenteral

*
Topical

Advanced Pancreatic Cancer Molecule Type

Advanced Pancreatic Cancer Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Advanced Pancreatic Cancer Pipeline Therapeutics Assessment

*
Advanced Pancreatic Cancer Assessment by Product Type

*
Advanced Pancreatic Cancer By Stage and Product Type

*
Advanced Pancreatic Cancer Assessment by Route of Administration

*
Advanced Pancreatic Cancer By Stage and Route of Administration

*
Advanced Pancreatic Cancer Assessment by Molecule Type

*
Advanced Pancreatic Cancer by Stage and Molecule Type

DelveInsight's Advanced Pancreatic Cancer Report covers around products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Advanced Pancreatic Cancer product details are provided in the report. Download the Advanced Pancreatic Cancer pipeline report to learn more about the emerging Advanced Pancreatic Cancer therapies [https://www.delveinsight.com/sample-request/advanced-pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Advanced Pancreatic Cancer Therapeutics Market include:

Key companies developing therapies for Advanced Pancreatic Cancer are - AB Science, AstraZeneca, Eleison Pharmaceuticals, ImmunityBio, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Incyte Corporation, AbbVie, Ability Pharmaceuticals SL, Legend Biotech USA Inc, Biomea Fusion Inc., Astellas Pharma Inc, Cue Biopharma, PureTech, and others.

Advanced Pancreatic Cancer Pipeline Analysis:

The Advanced Pancreatic Cancer pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Pancreatic Cancer with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Pancreatic Cancer Treatment.

*
Advanced Pancreatic Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Advanced Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Pancreatic Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Advanced Pancreatic Cancer drugs and therapies [https://www.delveinsight.com/sample-request/advanced-pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Advanced Pancreatic Cancer Pipeline Market Drivers

*
Emergence of genomic profiling technologies and selective molecular targeted therapies, emergence of effective therapeutic options for metastatic pool are some of the important factors that are fueling the Advanced Pancreatic Cancer Market.

Advanced Pancreatic Cancer Pipeline Market Barriers

*
However, delayed detection and screening of the disease, stromal barriers to drug delivery within the TME in Advanced Pancreatic Cancer and other factors are creating obstacles in the Advanced Pancreatic Cancer Market growth.

Scope of Advanced Pancreatic Cancer Pipeline Drug Insight

*
Coverage: Global

*
Key Advanced Pancreatic Cancer Companies: Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others

*
Key Advanced Pancreatic Cancer Therapies: IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others

*
Advanced Pancreatic Cancer Therapeutic Assessment: Advanced Pancreatic Cancer current marketed and Advanced Pancreatic Cancer emerging therapies

*
Advanced Pancreatic Cancer Market Dynamics: Advanced Pancreatic Cancer market drivers and Advanced Pancreatic Cancer market barriers

Request for Sample PDF Report for Advanced Pancreatic Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/advanced-pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Advanced Pancreatic Cancer Report Introduction

2. Advanced Pancreatic Cancer Executive Summary

3. Advanced Pancreatic Cancer Overview

4. Advanced Pancreatic Cancer- Analytical Perspective In-depth Commercial Assessment

5. Advanced Pancreatic Cancer Pipeline Therapeutics

6. Advanced Pancreatic Cancer Late Stage Products (Phase II/III)

7. Advanced Pancreatic Cancer Mid Stage Products (Phase II)

8. Advanced Pancreatic Cancer Early Stage Products (Phase I)

9. Advanced Pancreatic Cancer Preclinical Stage Products

10. Advanced Pancreatic Cancer Therapeutics Assessment

11. Advanced Pancreatic Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Advanced Pancreatic Cancer Key Companies

14. Advanced Pancreatic Cancer Key Products

15. Advanced Pancreatic Cancer Unmet Needs

16 . Advanced Pancreatic Cancer Market Drivers and Barriers

17. Advanced Pancreatic Cancer Future Perspectives and Conclusion

18. Advanced Pancreatic Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-pancreatic-cancer-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-incyte-abbvie-ability-pharma-ab-science-astrazeneca-eleison-pharma-immunitybio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.